Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Tuesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) will likely be issuing its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $2.32 on Monday. The business has a 50 day simple moving average of $2.55 and a 200-day simple moving average of $3.07. Zentalis Pharmaceuticals has a 12 month low of $1.61 and a 12 month high of $18.07. The stock has a market capitalization of $165.32 million, a P/E ratio of -0.93 and a beta of 1.81.

Insider Activity at Zentalis Pharmaceuticals

In related news, insider Ingmar Bruns acquired 20,000 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was bought at an average price of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now directly owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were purchased at an average price of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. HC Wainwright decreased their target price on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. UBS Group decreased their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Guggenheim decreased their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.